

Grifols is included on the Dow Jones Sustainability World Index and advances as one of the world's most sustainable companies

- *For the first time ever, Grifols has been included on the Dow Jones Sustainability World Index (DJSI World) while retaining its distinction on the Dow Jones Sustainability Europe Index (DJSI Europe)*
- *Grifols is recognized among the top six biotechnology companies globally and is the only European firm in its industry to join the DJSI World. This year, the number of companies assessed in this sector increased by 46%*
- *The DJSI, the world's leading sustainability index, evaluates companies' performance based on environmental, social and governance (ESG) criteria. In 2021, the index distinguished only 322 companies out of the more than 10,000 invited to take part*

Barcelona, November 15, 2021.- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines with a proven track record of more than 110 years contributing to people's health and well-being, has been recognized for the second consecutive year among the world's most sustainable companies by the Dow Jones Sustainability Indices (DJSI), the leading global sustainability index that evaluates companies' environmental, social and governance (ESG) performance.

Grifols' notable sustainability achievements in recent years have led to its first-ever distinction on the DJSI World Index, while to remain on the DJSI Europe Index, in which the company was first listed in 2020.

Grifols is among the top six worldwide leaders in its sector and the only European firm in its segment to join the DJSI World Index. This year, the number of companies assessed in the biotechnology industry increased by 46%.

Grifols' scores reflect its continuous improvement in all dimensions evaluated: Corporate Governance and Economic, Environmental and Social.

As co-CEOs Raimon Grifols and Víctor Grífols Deu observed, "Sustainability is a long-term commitment to which we have remained faithful since our origins. Grifols' distinction on the Dow Jones Sustainability World Index is an important step forward and a major recognition of

our constant efforts to drive growth based on transparency, the value of a job well done, ethical leadership and teamwork. We will continue to work in the same direction in benefit of the thousands of patients around the world who need our life-saving therapies and solutions, as well as for the planet and society as a whole.”

For the elaboration of the Dow Jones Sustainability Index, S&P Dow Jones applies a transparent, rules-based constituent selection process based on companies' S&P Global Corporate Sustainability Assessment (CSA). The CSA consists of an extended questionnaire assessing both public and non-public data submitted by participating companies. This year, more than 10,000 publicly traded companies were invited to participate in the S&P Global CSA.

Grifols has been recognized on the FTSE4Good Global, FTSE4Good Europe and FTSE4Good Ibox sustainability stock market indices since 2018, and on the Euronext Vigeo Europe 120 and Euronext Vigeo Eurozone 120 indices, based on the Vigeo Eiris assessment, since 2020. In 2021, Grifols was also included on the Bloomberg Gender-Equality Index (GEI) in recognition of its commitment to addressing gender inequality.

All of Grifols' sustainability information is public and available at [Grifols | Sustainability](#)

Investor contact:

Investor Relations and Sustainability

inversores@grifols.com - investors@grifols.com

sostenibilidad@grifols.com - sustainability@grifols.com

Tel. +34 93 571 02 21

Media contacts:

<p>Raquel Lumbreras Raquel_lumbreras@duomocomunicacion.com Borja Gómez Borja_gomez@duomocomunicacion.com Duomo Comunicación – Grifols Press Office Tel. +34 91 311 92 89 - 91 311 92 90 +34 659 57 21 85 / +34 650 40 22 25</p>	<p>Grifols Media Press Office media@grifols.com Tel. +34 571 00 02</p>
---	---

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with close to 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols' economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com



LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.